Table 2.
Confirmation of eEF1A2 and utrophin A protein expression level increases in C2C12 cells, post FDA-approved drug treatment.
| Drug | Utrophin A protein level (fold increase to veh ctl) | eEF1A2 protein level (fold increase to veh ctl) | Optimal concentration |
|---|---|---|---|
| Acarbose | 2.51 | 4.62 | 1 µM |
| Betaxolol | 2.13 | 4.26 | 5 µM |
| Labetalol·HCl | 3.25 | 1.41 | 1 µM |
| Telbivudine | 2.72 | 2.77 | 30 µM |
| Pravastatin·Na | 1.84 | 2.30 | 200 nM |
| Olsalazine·Na | 1.58 | 1.13 | 4 µM |
| Lovastatin | 1.34 | 1.12 | 100 nM |
| Nizatidine | 1.22 | No increase | 1 µM |
| Propylthiouracil | 1.17 | No increase | 10 µM |
| Hydrochlorothiazide | No increase | 1.44 | 5 µM |
| Rosiglitazone | No increase | 1.30 | 5 µM |
The drugs above the middle horizontal line are the five top drugs picked for further analysis in vitro and in vivo.